The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Bone Marrow Microenvironment in Multiple Myeloma Progression
Open accessAbstract
Substantial advances have been made in understanding the biology of multiple myeloma (MM) through the study of the bone marrow (BM) microenvironment. Indeed, the BM niche appears to play an important role in differentiation, migration, proliferation, survival, and drug resistance of the malignant plasma cells. The BM niche is composed of a cellular compartment (stromal cells, osteoblasts, osteoclasts, endothelial cells, and immune cells) and a noncellular compartment including the extracellular matrix (ECM) and the liquid milieu (cytokines, growth factors, and chemokines). In this paper we discuss how the interaction between the malignant plasma cell and the BM microenvironment allowed myeloma progression through cell homing and the new concept of premetastatic niche.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited
Fidler, I. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1098 · Cited by 4,686 · cited 3×
“However the new host microenvironment is not well adapted to the cancer cells that metastasized into it, leading to the new concept of premetastatic niche [8].”
BackgroundInfluentialMelanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
Peinado, H., Alečković, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., Hergueta-Redondo, M., Williams, C., García-Santos, G., Ghajar, C. M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2753 · Cited by 3,715
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059
The pathogenesis of cancer metastasis
Poste, G., & Fidler, I. J. (1980) · Nature · doi:10.1038/283139a0 · Cited by 1,739
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633
Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., & Shaughnessy, J. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030847 · Cited by 1,503
The metastatic niche: adapting the foreign soil
Psaila, B., & Lyden, D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2621 · Cited by 1,300
Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
Kyle, R. A., & Rajkumar, S. V. (2009) · Leukemia · doi:10.1038/leu.2008.291 · Cited by 1,121
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
Kyle, R. A., Durie, B. G. M., Rajkumar, S. V., Landgren, O., Blade, J., Merlini, G., Kröger, N., Einsele, H., Vesole, D. H., Dimopoulos, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.60 · Cited by 888
The role of Notch in tumorigenesis: oncogene or tumour suppressor?
Radtke, F., & Raj, K. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1186 · Cited by 785
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
Bergsagel, P. L., Kuehl, W. M., Zhan, F., Sawyer, J., Barlogie, B., & Shaughnessy, J. (2005) · Blood · doi:10.1182/blood-2005-01-0034 · Cited by 698
Advances in biology of multiple myeloma: clinical applications
Hideshima, T., Bergsagel, P. L., Kuehl, W. M., & Anderson, K. C. (2004) · Blood · doi:10.1182/blood-2004-01-0037 · Cited by 582
A monoclonal gammopathy precedes multiple myeloma in most patients
Weiss, B. M., Abadie, J., Verma, P., Howard, R. S., & Kuehl, W. M. (2009) · Blood · doi:10.1182/blood-2008-12-195008 · Cited by 569
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
Hideshima, T., Nakamura, N., Chauhan, D., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204833 · Cited by 478
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma
Alsayed, Y., Ngo, H., Runnels, J., Leleu, X., Singha, U. K., Pitsillides, C. M., Spencer, J. A., Kimlinger, T., Ghobrial, J. M., Jia, X., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035857 · Cited by 478
Self-citationYaccoby, S., Ling, W., Zhan, F., Walker, R., Barlogie, B., & Shaughnessy, J. D. (2007) · Blood · doi:10.1182/blood-2006-09-047712 · Cited by 433
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
Fulciniti, M., Tassone, P., Hideshima, T., Vallet, S., Nanjappa, P., Ettenberg, S. A., Shen, Z., Patel, N., Tai, Y.-T., Chauhan, D., et al. (2009) · Blood · doi:10.1182/blood-2008-11-191577 · Cited by 399
Pathogenesis of myeloma bone disease
Roodman, G. D. (2009) · Leukemia · doi:10.1038/leu.2008.336 · Cited by 398
The role of hypoxia in the maintenance of hematopoietic stem cells
Cipolleschi, M., Dello Sbarba, P., & Olivotto, M. (1993) · Blood · doi:10.1182/blood.v82.7.2031.2031 · Cited by 391
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Podar, K., & Anderson, K. C. (2005) · Blood · doi:10.1182/blood-2004-07-2909 · Cited by 343
Yaccoby, S., Pearse, R. N., Johnson, C. L., Barlogie, B., Choi, Y., & Epstein, J. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03257.x · Cited by 305
O'Brien, A. W. (1905) · The Elementary School Teacher · doi:10.1086/453500 · Cited by 303
Pathogenesis of myeloma bone disease
Roodman, G. D. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22403 · Cited by 296
Chauhan, D., Kharbanda, S., Ogata, A., Urashima, M., Teoh, G., Robertson, M., Kufe, D. W., & Anderson, K. C. (1997) · Blood · doi:10.1182/blood.v89.1.227 · Cited by 272
Nefedova, Y., Cheng, P., Alsina, M., Dalton, W. S., & Gabrilovich, D. I. (2004) · Blood · doi:10.1182/blood-2003-07-2340 · Cited by 270
Sanz-Rodrı́guez, F., Hidalgo, A., & Teixidó, J. (2001) · Blood · doi:10.1182/blood.v97.2.346 · Cited by 249
Lust, J. A., Lacy, M. Q., Zeldenrust, S. R., Dispenzieri, A., Gertz, M. A., Witzig, T. E., Kumar, S., Hayman, S. R., Russell, S. J., Buadi, F. K., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.2.114 · Cited by 246
Nowakowski, G. S., Witzig, T. E., Dingli, D., Tracz, M. J., Gertz, M. A., Lacy, M. Q., Lust, J. A., Dispenzieri, A., Greipp, P. R., Kyle, R. A., et al. (2005) · Blood · doi:10.1182/blood-2005-05-1858 · Cited by 245
Bataille, R., Chappard, D., Marcelli, C., Dessauw, P., Sany, J., Baldet, P., & Alexandre, C. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.12.1909 · Cited by 241
Shipman, C. M., & Croucher, P. I. (2003) · PubMed · Cited by 241
Korde, N., Kristinsson, S. Y., & Landgren, O. (2011) · Blood · doi:10.1182/blood-2011-01-270140 · Cited by 199
Lapidot, T. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03577.x · Cited by 196
Myeloma as a model for the process of metastasis: implications for therapy
Ghobrial, I. M. (2012) · Blood · doi:10.1182/blood-2012-01-379024 · Cited by 188
Self-citationTanaka, Y., Abe, M., Hiasa, M., Oda, A., Amou, H., Nakano, A., Takeuchi, K., Kitazoe, K., Kido, S., Inoue, D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2258 · Cited by 177
Edwards, C. M., Edwards, J. R., Lwin, S. T., Esparza, J., Oyajobi, B. O., McCluskey, B., Munoz, S., Grubbs, B., & Mundy, G. R. (2008) · Blood · doi:10.1182/blood-2007-03-077685 · Cited by 160
Interleukin-6 is a prognostic factor in multiple myeloma [letter] [see comments]
Ludwig, H., Nachbaur, D., Fritz, E., Krainer, M., & Huber, H. (1991) · Blood · doi:10.1182/blood.v77.12.2794.2794 · Cited by 158 · cited 1×
“Clinically, elevated serum IL-6 levels are associated with a poor prognosis and reflect the proliferation fraction of MM cells within patients [35].”
BackgroundExpression of VEGF and its receptors by myeloma cells
Kumar, S. K., Witzig, T. E., Timm, M., Haug, J., Wellik, L. E., Fonseca, R., Greipp, P. R., & Rajkumar, S. V. (2003) · Leukemia · doi:10.1038/sj.leu.2403084 · Cited by 151
Angiogenesis and Multiple Myeloma
Giuliani, N., Storti, P., Bolzoni, M., Palma, B. D., & Bonomini, S. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0072-9 · Cited by 129
A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma
Rajkumar, S. V., & Witzig, T. E. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0188 · Cited by 123
IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms
De Bruyne, E., Bos, T. J., Schuit, F., Van Valckenborgh, E., Menu, E., Thorrez, L., Atadja, P., Jernberg-Wiklund, H., & Vanderkerken, K. (2010) · Blood · doi:10.1182/blood-2009-07-232801 · Cited by 103
Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma
Ria, R., Todoerti, K., Berardi, S., Coluccia, A. M. L., Luisi, A. D., Mattioli, M., Ronchetti, D., Morabito, F., Guarini, A., Petrucci, M. T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0040 · Cited by 103
The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma
Ehrlich, L. A., & Roodman, G. D. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00323.x · Cited by 94
Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts
Karadağ, A., Oyajobi, B. O., Apperley, Russell, R. G. G., & Croucher, P. I. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.01845.x · Cited by 78
Kumar, S. K., Gertz, M. A., Dispenzieri, A. A., Lacy, M. Q., Wellik, L. E., Fonseca, R., Lust, J. A., Witzig, T. E., Kyle, R. A., Greipp, P. R., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704555 · Cited by 76
Cited by
Wang, J., Hendrix, A., Hernot, S., Lemaire, M., De Bruyne, E., Van Valckenborgh, E., Lahoutte, T., De Wever, O., Vanderkerken, K., & Menu, E. (2014) · Blood · doi:10.1182/blood-2014-03-562439 · Cited by 441
Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204
The role of CXCR4 in multiple myeloma: Cells’ journey from bone marrow to beyond
Ullah, T. R. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2019.100253 · Cited by 141
The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma
Vrábel, D., Pour, L., & Ševčíková, S. (2019) · Blood Reviews · doi:10.1016/j.blre.2018.11.003 · Cited by 123
Maiso, P., Mogollón, P., Ocio, E. M., & Garayoa, M. (2021) · Cancers · doi:10.3390/cancers13112542 · Cited by 48
Metadata
- Authors
- Manier, S., Sacco, A., Leleu, X., Ghobrial, I. M., & Roccaro, A. M.
- Venue
- Journal of Biomedicine and Biotechnology
- Publisher
- Hindawi Limited
- Published
- 2012
- Volume
- 2012
- Pages
- 1-5
- ISSN
- 1110-7243 (ISSN-L)
- 1110-7251
- OpenAlex
- W2116619860
- Cited by
- 301
- References
- 48
- FWCI
- 10.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.